TY  - JOUR
AU  - Bochtler, Tilmann
AU  - Reiling, Anna
AU  - Endris, Volker
AU  - Hielscher, Thomas
AU  - Volckmar, Anna-Lena
AU  - Neumann, Olaf
AU  - Kirchner, Martina
AU  - Budczies, Jan
AU  - Heukamp, Lukas C
AU  - Leichsenring, Jonas
AU  - Allgäuer, Michael
AU  - Kazdal, Daniel
AU  - Löffler, Harald
AU  - Weichert, Wilko
AU  - Schirmacher, Peter
AU  - Stenzinger, Albrecht
AU  - Krämer, Alwin
TI  - Integrated clinico-molecular characterization identifies RAS activation and CDKN2A deletion as independent adverse prognostic factors in cancer of unknown primary.
JO  - International journal of cancer
VL  - 146
IS  - 11
SN  - 1097-0215
CY  - Bognor Regis
PB  - Wiley-Liss
M1  - DKFZ-2020-00267
SP  - 3053-3064
PY  - 2020
N1  - 2020 Jun 1;146(11):3053-3064#EA:A360#LA:A360#
AB  - Cancer of unknown primary (CUP) denotes a malignancy with histologically confirmed metastatic spread while the primary tumor remains elusive. Here, we address prognostic and therapeutic implications of mutations and copy number variations (CNVs) detected in tumor tissue in the context of a comprehensive clinical risk assessment. Targeted panel sequencing was performed in 252 CUP patients. 71.8
LB  - PUB:(DE-HGF)16
C6  - pmid:31970771
DO  - DOI:10.1002/ijc.32882
UR  - https://inrepo02.dkfz.de/record/153234
ER  -